Bipolar depression: trial-based insights to guide patient care by Kemp, David E. et al.
Background
lthough mania and hypomania are the essen-
tial and more florid features of bipolar disorder,debili-
tating depressive symptoms and episodes dominate the
longitudinal course,and are less responsive to treatment.
Moreover,the initial presentation of bipolar disorder is
often depression,which delays the establishment of the
correct diagnosis and initiation of appropriate guideline
concordant care.During the past decade,there has been
a growing appreciation of the harmful dysfunction asso-
ciated with depression as part of bipolar disorder. For
example,patients diagnosed with and/or screening posi-
tive for bipolar disorder evince greater deficits in work,
social,and family functioning when experiencing depres-
sive versus manic symptoms.
1 Similarly,in a systematic
20-year prospective study,Judd and colleagues
2 identified
minor depression or dysthymia to be more disabling than
hypomania,as well as a trend for major depression to be
more impairing than mania.Across the bipolar (BP) I
and II subtypes,a parallel gradient between the level of
psychosocial impairment and severity of depressive
symptoms has been documented. The risk of suicide,
which averages 0.4% per year among patients with bipo-
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For the majority of patients with bipolar disorder, major
depressive episodes represent the most debilitating and
difficult-to-treat illness dimension. Patients spend signifi-
cantly more time depressed than manic or hypomanic,
and attempt suicide more frequently during this illness
phase, yet the availability of treatments remains limited.
The discovery of more effective therapeutics for manag-
ing depressive episodes is arguably the greatest unmet
need in bipolar disorder. This article provides an evidence-
based summary of pharmacological treatments for the
acute and longitudinal management of bipolar depres-
sion. Clinical trial results are reviewed for a diverse array
of compounds, inclusive of traditional mood stabilizers
(eg, lithium and divalproex), atypical antipsychotics, uni-
modal antidepressants, and modafinil. Where applicable,
differences in efficacy across compounds are examined
through discussion of number needed to treat and effect
size determinations. A pragmatic clinical approach is pre-
sented for management of the depressed phase of bipo-
lar disorder.
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:181-192.lar disorder, also appears greater during phases of
depression and dysphoric-agitated mixed states than dur-
ing mania.
3
Severely disrupting the life course of afflicted individu-
als,bipolar disorder is associated with high rates of unem-
ployment,
4 medical comorbidity,
5 decreased work pro-
ductivity,
6 and a reduced quality of life.
7 Even when
symptoms are subsyndromal in nature,impairments in
role functioning are frequently apparent.
8
Collectively,the high morbidity and mortality associated
with bipolar depression warrants considerable attention.
Despite intensified efforts to characterize the antimanic
effects of atypical antipsychotics,relatively few studies
had tested these agents in bipolar depression.For exam-
ple,of the seven available atypical agents in the US,five
have been studied in pivotal randomized,placebo-con-
trolled acute mania registration trals prior to the initia-
tion of the first placebo-controlled trial of an atypical
antipsychotic (ie,quetiapine) in bipolar depression.
Longitudinal observations which aim to characterize the
symptomatic structure of bipolar disorder have high-
lighted its pleomorphic and changeable symptomatic
expression.Bipolar disorder is more accurately catego-
rized as a dimensional (versus modal) phenomenon,with
substantial intraindividual shifts in polarity and symptom
expression from threshold to subsyndromal severity.
Patients with BP-I self-report depressive symptoms three
times more frequently than manic symptoms.
9An even
greater depressive burden is reported by patients with
BP-II,who experience some degree of depressive symp-
toms during more than half of all weeks during longitu-
dinal follow-up.
10 Individuals with BP-II disorder spend
nearly 40 times more days depressed than hypomanic
and more days cycling or in a mixed state.However,it is
possible that retrospective recall bias influenced this
data,since patients are more likely to recall episodes of
depression than episodes of hypomania.
11When assess-
ing mood state prospectively, through the use of daily
life-charting methodology, the ratio of depression to
mania/hypomania was found to be similar in subjects
with BP-I or II.
12 Nevertheless,the burden of depression
in bipolar disorder is consistent with recent findings from
the NIH-sponsored Systematic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD).
13 In this
STEP-BD report evaluating the effectiveness of guide-
line-based care, mood episode recurrence among 858
patients followed a median of 56.2 weeks after recovery
and was experienced by 48.5% of the cohort, with
depressive episodes comprising the majority of recur-
rences (70%).Observations of lower acute recovery rates
and longer time to remission from an index depressive
episode further underscore the clinical challenge in man-
aging bipolar depression.
During the past decade,a growing number of randomized
controlled trials have added to the empirical basis for
selecting and sequencing treatments for bipolar depres-
sion.The overarching objective of this article is to provide
practitioners with an evidence-based summary of the phar-
macological treatments for bipolar depression.
We conducted a PubMed search of all English-language
articles published between January 1966 and July 2007.
The search was limited to randomized, double-blind,
placebo-controlled trials for the treatment of acute bipo-
lar depression.The search was augmented with a manual
review of article reference lists and conference proceed-
ings.Articles prioritized for review were based on ade-
quacy of sample size (ie,an enrolled sample size ≥40 sub-
jects),the use of standardized experimental procedures,
validated assessment measures, and author consensus
regarding overall manuscript quality.
Unimodal antidepressants in the 
management of bipolar depression
There is genuine complexity in the role of conventional
unimodal antidepressants in the acute and/or mainte-
nance treatment of bipolar depression. Despite the
absence of large,adequately powered,randomized con-
trolled trials in bipolar disorder,antidepressants are fre-
quently prescribed as monotherapy and adjunctively to
other conventional mood-stabilizing therapies.The haz-
ard for treatment of urgent affective switching and cycle
acceleration are well characterized, particularly in the
context of antidepressant monotherapy.A recent meta-
analysis of heterogeneous trials involving conventional
antidepressants in bipolar disorder suggested that the
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Selected abbreviations and acronyms
5-HT serotonin
BOLDER Bipolar Depression Studies (quetiapine)
BP bipolar disorder
CGI Clinical Global Impressions 
MADRS Montgomery-Asberg Depression Rating Scale
OFC olanzapine-fluoxetine combination
STEP-BD Systematic Treatment Enhancement Program
for Bipolar Disordertherapeutic index of these treatments is not unfavor-
able.
14 These results, however, are at odds with recent
findings from the STEP-BD program which evaluated
the efficacy,safety,and tolerability of adjunctive antide-
pressants in bipolar disorder.
15 In this trial,patients with
BP-I or II were randomly assigned to treatment with
bupropion, paroxetine, or placebo added to an FDA-
approved antimanic agent. The trial employed an
equipoise-stratified randomization design;thus,psychia-
trists could choose from three strata (placebo vs bupro-
pion,placebo vs paroxetine,or placebo vs either antide-
pressant) to allow research participation, even if the
patient held a clear preference for one antidepressant
versus another.A total of 366 patients enrolled in the
study and were randomized to receive either a mood sta-
bilizer plus placebo (N=187) or a mood stabilizer plus an
antidepressant (N=179).
As opposed to simple measurements of response,
durable recovery was uniquely chosen as the primary
outcome measure, defined as a state of euthymia for 8
consecutive weeks.Secondary outcomes included tradi-
tional rates of response based on a ≥50% improvement
on the Structured Clinical Interview for DSM-IV con-
tinuous symptom subscale for depression. In the end,
rates of durable recovery were similar between the anti-
depressant (23.5%) and placebo (27.3%) groups (P=0.4).
Response rates also did not differ between groups,and
BP-I subjects were as likely to respond (25.4%) as were
BP-II subjects (20.4%). Adjunctive antidepressant
administration was not found to confer a greater benefit
than mood-stabilizer monotherapy in the treatment of
bipolar depression.Additionally,antidepressants were
not associated with an increase in cycling between the
depressive and manic poles.In summary,the study found
neither an advantage nor disadvantage associated with
use of the antidepressants bupropion or paroxetine.
Conventional mood stabilizers 
and atypical antipsychotics
Lithium
Although lithium is the oldest agent studied for the acute
treatment of bipolar depression,it remains a viable and
underutilized option with established efficacy in various
trial designs and clinical experience.Zornberg and Pope,
16
in a comprehensive review of controlled investigations
of lithium, identified eight studies that demonstrated
lithium to be more effective than placebo in the treat-
ment of acute bipolar depression.Nevertheless,most of
the constituent studies in their analysis were older inves-
tigations (ie,published prior to 1978),or limited by sev-
eral methodological shortcomings. For instance, our
search strategy was unable to identify any moderately
sized studies of lithium for the acute treatment of bipo-
lar depression. Furthermore, early trials employed
crossover as opposed to parallel designs introducing the
possibility for carryover effects.The abrupt discontinu-
ation of lithium may also have biased efficacy assess-
ments,as acute withdrawal of lithium leads to,and has-
tens, a high probability of relapse.
17 Since most pivotal
randomized control trials with pharmacological agents
are designed primarily for registration purposes,the lack
of commercial interest in this compound provides partial
explanation for its understudy in bipolar depression.
A more recent study by Nemeroff and colleagues
18 eval-
uated and compared the efficacy of adjunctive paroxe-
tine or imipramine to lithium in the treatment of BP-I
depression as part of a randomized, double-blind,
placebo-controlled trial. Among the total sample
(n=117), placebo was as effective as paroxetine or
imipramine on continuous measures of depression.
However,among patients stratified on the basis of low
lithium levels (≤0.8 mEq/L), both paroxetine and
imipramine were superior to placebo.These data provide
indirect, yet controlled evidence for lithium’s plasma
level-dependent (ie,0.8 mEq/L or higher) efficacy.A fur-
ther asset attributed to lithium is its ability to lower mor-
tality due to completed and attempted suicide in popu-
lations of individuals with bipolar disorder.
19
Lithium-treated patients may be less likely to attempt
suicide,require hospitalization for suicidal behavior,or
complete suicide than bipolar patients treated with either
valproate or carbamazepine.
20 Despite the advantages
attributed to lithium,this cation is associated with many
unacceptable side effects, a low rate of adherence, the
need for plasma level monitoring,thyroid and renal sur-
veillance,and serious safety concerns in overdose.
Lamotrigine
The anticonvulsant lamotrigine was the first compound
studied for the acute treatment of BP-I depression in a
large-scale, randomized, double-blind, parallel-group,
placebo-controlled design.
21 In this initial 7-week efficacy
trial, 195 subjects were randomized to lamotrigine 50
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183mg/day,lamotrigine 200 mg/day,or placebo.By week 3,
whereas all subjects were receiving lamotrigine 50
mg/day,a significant difference was observed between
both of the active treatment arms and placebo.However,
at trial conclusion,only the lamotrigine 200 mg/day dose
was superior to placebo at reducing depressive symptoms
as measured by the Montgomery-Asberg Depression
Rating Scale (MADRS), Clinical Global Impressions-
Improvement (CGI-I),and Clinical Global Impressions-
Severity (CGI-S) scales. Rates of response (≥50%
decrease in MADRS total score) were greater with lam-
otrigine than placebo,regardless of whether a dose of 50
or 200 mg/day was administered.
After completion of this 7-week trial, four additional
placebo-controlled monotherapy studies of lamotrigine
were conducted in patients experiencing an acute episode
of bipolar depression.
22Two trials enrolled subjects with
BP-I,one study enrolled subjects with BP-II,and another
enrolled subjects with either BP-I or II.In each of these
4 studies,neither the mean-change-from-baseline scores
on the MADRS or Hamilton Depression Rating Scale
(HAM-D;17-item scale),nor the percentage of treatment
responders on the MADRS or HAM-D,differed signifi-
cantly between lamotrigine and placebo. In each of the
studies,the placebo response rates were generally quite
high,ranging from 39% to 49%.Conceivably,the only sig-
nal for antidepressant efficacy appeared in the trial of BP-
II subjects,where the percentage of CGI-I responders was
higher in the lamotrigine group (61% vs 45%, P<0.05).
This finding is consistent with a previous maintenance trial
of lamotrigine in rapid-cycling bipolar disorder,where sub-
jects with BP-II demonstrated a significantly greater study
survival than placebo-treated subjects.
23 In all five multi-
center monotherapy depression studies of lamotrigine
completed to date, the drug was well tolerated, with
headache,nausea,and rash representing the most common
side effects.No reports of serious rash occurred in any of
the acute bipolar depression trials.
Thus far,the five clinical trials pertaining to lamotrigine
as discussed in this review have focused entirely on its
use as a monotherapy for bipolar depression.Recently,
however,investigators from the Netherlands and Spain
have expanded the assessment of lamotrigine to explore
its efficacy as an add-on treatment to lithium for the
management of BP-I or II.
24 Subjects who remained
depressed despite adequate treatment with lithium
(plasma levels 0.6 to 1.2 mmol/L) were subsequently ran-
domized to lamotrigine or placebo for 8 weeks of dou-
ble-blind therapy.Among the 124 subjects (68% BP-I
and 32% BP-II), a significant change on the MADRS
total score from baseline to end point was evinced in the
lamotrigine group (-15.38 points vs -11.03 points;
P=0.024).In this study,the MADRS proved a more sen-
sitive indicator of antidepressant response than CGI-BP
scores,with 51.6% of subjects achieving ≥50% reduction
in MADRS total score as compared with 31.7% in the
placebo group (P=0.03).Statistical separation with lam-
otrigine was noticeable as early as week 4.
These findings add to a growing literature that supports
the use of lamotrigine in acute bipolar depression, but
suggests the agent may play an important role as an
adjunct to conventional mood stabilizers. In a second
phase of this study,
24 nonresponders to combination treat-
ment (lithium plus lamotrigine or lithium plus placebo)
were subsequently administered paroxetine in an open-
label fashion for an additional 8 weeks.At the end-point
assessment,no significant difference in MADRS score
reduction was observed between treatment arms.As all
of the initial nonresponders received paroxetine without
the use of a placebo control, it is unknown whether
paroxetine truly provided antidepressant benefit, or
whether a subgroup of subjects merely required a longer
duration of treatment with lamotrigine to attain a simi-
lar magnitude of improvement.Overall,triple therapy
with lithium,lamotrigine,and paroxetine did not appear
to result in greater symptom reduction than the combi-
nation of lithium and paroxetine.
Carbamazepine and divalproex
Even though carbamazepine is widely utilized in the
treatment of bipolar disorder,we were unable to identify
any randomized,parallel,placebo-controlled trials eval-
uating this agent in acute bipolar depression.The inter-
pretation of results from earlier trials of carbamazepine
were complicated by several methodological issues
including crossover designs and evaluation of mixed
cohorts containing unipolar and bipolar subjects.
25,26
Initial interest in the use of divalproex monotherapy for
bipolar depression was provided by an open study that
suggested benefit in medication-naïve subjects with BP-
II.
27 Subsequently,Sachs and colleagues conducted the
first multicenter trial comparing divalproex with placebo
in 43 subjects with bipolar depression (types I,II,or not
otherwise specified).
28 In this 8-week study,no significant
difference was observed between treatment arms in
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mean change from baseline on the HAM-D.Two smaller
controlled trials in bipolar depression have been con-
ducted that demonstrate superiority of monotherapy
divalproex over placebo.
29,30 In total,the controlled trial
evidence evaluating divalproex in bipolar depression
rests on the outcomes of 87 patients spread across three
separate trials.This limited population size beckons for
larger studies to confirm or refute findings that suggest
divalproex may wield independent antidepressant effi-
cacy in bipolar disorder.
Olanzapine and the olanzapine-fluoxetine combination
In 2003, an olanzapine-fluoxetine combination (OFC)
was the first compound approved by the US FDA for the
treatment of bipolar depression.This decision directed
attention to the atypical antipsychotic drugs as appealing
considerations for treating both the manic and depressed
phases of bipolar disorder.The evidence for OFC’s effi-
cacy on categorical and continuous measures of depres-
sion was derived from two pooled,8-week,placebo-con-
trolled trials comparing olanzapine monotherapy and
OFC against placebo in BP-I depression.
31 On the pri-
mary outcome measure of change from baseline to end-
point severity in MADRS score,as well as key secondary
measures including rates of response and remission,olan-
zapine- and OFC-treated subjects achieved significantly
greater improvement than placebo-treated subjects.An
analysis of individual MADRS items showed OFC to
improve sadness,reported sadness,lassitude,the inabil-
ity to feel,and pessimistic thoughts;whereas olanzapine
monotherapy improved more vegetative symptoms of
depression—reduced sleep,reduced appetite,and inner
tension.Neither compound was found to reduce suicidal
thinking. The clinical appeal of OFC is tempered by
metabolic concerns of weight gain and hyperglycemia
that are more highly associated with olanzapine than
with other atypical antipsychotics.
32
Quetiapine
Quetiapine is the only monotherapeutic agent approved
by the US FDA for acute bipolar depression.
Quetiapine’s approval for bipolar depression in 2006 was
based on results of two identically-designed pivotal trials
conducted in the US.A unique design feature of the que-
tiapine development program in bipolar depression was
the inclusion of individuals with BP-II disorder.In the
first of these companion trials, collectively termed the
BOLDER (BipOLar DEpRession) studies,360 patients
with BP-I and 182 patients with BP-II were randomized
to receive 8 weeks of treatment with either quetiapine
600 mg/day,300 mg/day,or placebo.
33A significant reduc-
tion in baseline-to-end point MADRS total score was
evidenced in both of the quetiapine arms over placebo.
Similarly, rates of response and remission were also
higher in quetiapine-treated subjects.A subgroup analy-
sis,however,did not find subjects with BP-II to demon-
strate a significant improvement on the primary outcome
measure at the 8-week end point. Unlike olanzapine
monotherapy,an analysis of individual MADRS items
showed quetiapine to not only reduce the core symptoms
of depression, but to also lower suicidal thoughts to a
greater extent than placebo.
A confirmatory study,BOLDER II,replicated the initial
findings in BOLDER I,providing additional support for
a specific antidepressant effect with quetiapine.
34Although
the magnitude of the overall treatment effect was smaller
than observed in BOLDER I, both the quetiapine 600
mg/day and 300 mg/day doses were superior to placebo at
reducing depressive symptoms.This effect was maintained
regardless of the bipolar subtype (type I or II) or the pres-
ence of rapid-cycling,a course specifier traditionally asso-
ciated with poor treatment response.There was no indi-
cation that larger doses of quetiapine provided additional
antidepressant benefit,suggesting that a total daily dose
of 300 mg be the recommended target.
In an attempt to explain quetiapine’s antidepressant
activity, Goldstein and colleagues
35 have recently
reported that norquetiapine, the dealkylated active
metabolite of quetiapine,possesses very high affinity for
serotonin (5-HT)2A receptors (Ki=3nM).Since (positron
emission tomography (PET) studies indicate that selec-
tive serotonin reuptake inhibitors (SSRIs),serotonin nor-
epinephrine reuptake inhibitors (SNRIs),and electro-
convulsive therapy also downregulate the 5-HT2A
receptor,this point of mechanistic commonality may pro-
vide explanation for quetiapine’s relatively robust and
broad spectrum effect in mood disorders. In addition,
Goldstein also reported that norquetiapine binds with
high affinity to the 5-HT2C receptor (Ki=18.5 nM),acts
as a potent inhibitor of the noradrenergic transporter,
and exerts partial agonist activity at the 5-HT1A receptor.
Partial agonist effects at 5-HT1A receptors may implicate
frontal cortex dopamine release as an alternative expla-
nation for the efficacy of quetiapine in depression.Aripiprazole
As a class,the atypical antipsychotics have demonstrated
clear superiority over placebo in the treatment of acute
mania.Emerging evidence,however,urges restraint in
assuming that all atypicals share similar efficacy for the
treatment of acute depressive episodes in bipolar disor-
der.This point is illustrated by recent data involving the
dopamine partial agonist aripiprazole.Predicated upon
uncontrolled reports suggesting aripiprazole might
improve depressive symptoms in treatment-resistant
unipolar major depressive disorder
36 and bipolar disor-
der,
37,38 two identical multicenter,double-blind trials were
conducted to compare aripiprazole with placebo in BP-
I subjects experiencing a nonpsychotic major depressive
episode.
39 Subjects were entered into an 8-week trial and
initiated on aripiprazole 10 mg daily (5 mg twice daily),
then flexibly dosed to 5 to 30 mg/day.In both studies,a
pattern of early statistical significance emerged,but dur-
ing later study weeks this separation dissipated.By the
trial end point, no significant difference was found in
either of the two trials on the primary efficacy measure
of mean change from baseline-to-end point score on the
MADRS.Similarly,no differences were observed on any
of the secondary efficacy measures.When pooling study
results,a large proportion of subjects receiving aripipra-
zole developed akathisia (24.4%) as compared with
placebo-treated subjects (3.8%).It is unknown whether
attempts to prevent or mitigate akathisia by initiating
aripiprazole at doses lower than 10 mg/day or by aggres-
sive and early use of β-blockers have the potential to
enhance tolerability and improve measured efficacy.
A summary of the trials discussed above can be seen in
Table I.
Gauging clinical efficacy
One means of comparing treatment effects among differ-
ent agents is through the use of effect size determinations
(improvement over placebo divided by pooled standard
deviation).With olanzapine monotherapy,the effect size
was small (0.32) but became moderate (0.68) with the
addition of fluoxetine in bipolar I depression.
31The advan-
tage of OFC over olanzapine alone was of the same mag-
nitude as the difference favoring olanzapine alone over
placebo.
40 In BOLDER I,the effect size of quetiapine was
large (~0.9) for both the 600 and 300 mg/day groups,
33 but
in the replication trial decreased to a moderate size.
34
Apart from effect size determinations,an alternate means
of translating research findings into clinically relevant
terms is through calculation of the number needed to treat
(NNT =1/responders on active compound minus respon-
ders on placebo). The NNT represents the number of
patients who would require treatment with the drug under
investigation in order for one additional patient to achieve
the desired outcome. Hence, the NNT is a pragmatic
means of comparing the magnitude of categorical
response across various drug treatments.Cookson and col-
leagues
41 calculated the NNT for rates of response and
remission in the 8-week BOLDER I trial.At study con-
clusion,the NNT values to achieve response (≥50% reduc-
tion in MADRS score) for both the quetiapine 600 and
300 mg/day dose were 5 (95% CI,4-9).This indicates that
5 patients would require treatment with quetiapine in
order for 1 additional patient to achieve a response as
compared with placebo. Data from other large bipolar
depression trials reveal the NNT values to be 12 for olan-
zapine (95% CI,7-62),4 for OFC (95% CI,3-8),and 4 for
lamotrigine 200 mg/d (95% CI,3-10).However,as the four
negative trials with lamotrigine had not yet been released
at the time of this analysis,the true NNT for lamotrigine
is likely to be much higher.It should also be noted that the
NNT may vary according to the baseline clinical and
demographic profile of the enrolled subjects.Thus,cross-
study comparisons should be interpreted with caution.
Treatment-refractory bipolar depression
Our review identified only one randomized trial that eval-
uated pharmacological agents for the relief of treatment-
resistant bipolar depression.
42 This study assessed the
adjunctive benefit of adding open inositol,lamotrigine,or
risperidone to conventional mood stabilizers.Criteria for
treatment-resistant depression,defined as being nonre-
sponsive to a mood stabilizer plus one or two antidepres-
sant trials during a major depressive episode,was met by
each of the 66 subjects.After up to 16 weeks of treatment,
no difference in the rate of recovery (8 weeks of ≤ 2 DSM-
IV threshold criteria for a major depressive, manic, or
hypomanic episode) was observed for subjects taking lam-
otrigine (24%),inositol (17%),or risperidone (5%).
Maintenance treatment of bipolar depression
Upon achieving an acute antidepressant response in
bipolar disorder,the conventional wisdom is to maintain
Pharmacological aspects
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reduction.An exception to this tenet involves the use of
conventional antidepressants,where some authors have
argued for antidepressant discontinuation after approx-
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Agent(s) and author Study duration/ Number completed/ Responders
a / Reduction in MADRS 
diagnostic subtype enrolled (%) remitters (%) or IDS-C (P)
Atypical antipsychotic monotherapy
Aripiprazole Thase et al, 2008
39 8 weeks ARP: 99/186 (53) ARP: 43.2/30.2;  P=NSc
BP-I PBO: 122/188 (65) PBO:39.0/27.8
Aripiprazole Thase et al, 2008
39 8 weeks ARP: 110/187 (59) ARP: 44.6/25.7;  P=NSc
BP-I PBO: 132/188 (70) PBO: 44.3/29.0
Olanzapine Tohen et al, 2003
31 8 weeks OLZ: 179/370 (48) OLZ: 39.0 / 32.8 OLZ: 15.0
c
BP-I PBO: 145/377 (38) PBO: 30.4 / 24.5 PBO: 11.9
c (P=.002)
Quetiapine Calabrese et al, 2005
33 8 weeks QUE: 219/361 (61) QUE: 58.0 / 52.9 QUE 600 mg/d: 16.73
c
BP-I or II PBO: 107/181 (59) PBO: 36.1 / 28.4 QUE 300 mg/d: 16.39
c
PBO: 10.26 (P<.001)
Quetiapine Thase et al, 2006
34 8 weeks QUE: 191/341 (56) QUE: 59.2 / 52.0 QUE 600 mg/d: 16.00
c
BP-I or II PBO: 110/168 (65) PBO: 44.7 / 37.3 QUE 300 mg/d: 16.94
c
PBO: 11.93c (P<.001)
Anticonvulsant monotherapy
Lamotrigine Calabrese et al, 1999
21 7 weeks LAM: 88/129 (68) LAM: 51.0 / NA LAM 50 mg/d: 11.2
c
BP-I PBO: 47/66 (71) PBO: 29.0 / NA LAM 200 mg/d: 13.3
c
PBO: 7.8
c (P<.05 )
b,
Lamotrigine Calabrese et al, 2008
22 10 weeks LAM: (66) LAM: 50.0 / NA LAM: 12.0
c
BP-I or II (SCAA2010) PBO: (67) PBO: 49.0 / NA PBO: 12.3
c (P=NS)
Lamotrigine Calabrese et al, 2008
22 8 weeks LAM: (61) LAM: 46.0 / NA LAM: 12.2
c
BP-I (SCA40910) PBO: (73) PBO: 39.3 / NA PBO: 11.2
c (P=NS)
Lamotrigine Calabrese et al, 2008
22 8 weeks LAM: (73) LAM: 45.5 / NA LAM: 13.4
c
BP-II (SCA100223) PBO: (67) PBO: 40.0 / NA PBO: 12.0
c (P=NS)
Lamotrigine Calabrese et al, 2008
22 8 weeks LAM: (60) LAM: 54.1 / NA LAM: 12.6
c
BP-I (SCA30924) PBO: (57) PBO: 45.7 / NA PBO: 11.7
c (P=NS)
Psychostimulant monotherapy
Modafinil Frye et al, 2007
55 6 weeks MOD: 29/41 (71) MOD: 43.9 / 22.7 MOD: 10.5
d
BP-I or II PBO: 29/44 (66) PBO: 39.0 / 18.0 PBO: 5.82
d (P=.04)
Combination therapy
Antidepressant Sachs et al, 2007
15 26 weeks MS + AD: 63/179 (35)
e MS + AD: 32.4 / 23.5
f NS
add-on to  BP-I or II MS + PBO: 63/187 (34)
e MS + PBO: 38.0 / 27.3
f
mood stabilizer
Lamotrigine  van der Loos et al, 2007
24 8 weeks Li + LAM: 52/64 (81) Li + LAM: 51.6 / NA Li + LAM: 15.38
c
add-on to  BP-I or II Li + PBO: 50/60 (83) Li + PBO: 31.7 / NA Li + PBO: 11.03
c
lithium (P=.024)
Olanzapine- Tohen et al, 2003
31 8 weeks OFC: 55/86 (64) OFC: 56.1 / 48.8 OFC: 18.5
c
fluoxetine  BP-I PBO: 145/377 (38) PBO: 30.4 / 24.5 PBO: 11.9
c
combination (P<.001)
Table I. Pharmacological treatments for bipolar depression: a summary of randomized, double-blind, parallel-group, placebo-controlled trials enrolling
≥40 subjects. ARP, aripiprazole; AST, aspartate aminotransferase; IDS-C, Inventory of Depressive Symptomatology-Clinician Rated Scale;
LAM, lamotrigine; MADRS, Montgomery-Asberg Depression Rating Scale; MOD, modafinil; MS, mood stabilizer; NA, data not available;
OFC, olanzapine-fluoxetine combination; OLZ, olanzapine; PBO, placebo; QUE, quetiapine; NS, nonsignificant 
aDefined as a ≥50% reduction in MADRS total score; 
bP<.05 only for the lamotrigine 200 mg/day dose; 
cReduction in MADRS score; 
dReduction
in IDS-C score; 
eCompleted 16 weeks of treatment; 
fResponded by week 16 imately 6 months of use in order to avoid cycle accelera-
tion or induction of mood switches above baseline.
43The
negative STEP-BD data now call into question the entire
practice of using antidepressants in either the acute or
continuation phase treatment of bipolar depression,and
unexpectedly do not suggest that antidepressants pro-
mote treatment-emergent affective switch.As this trial
did not extend beyond 26 weeks,maintenance trials in
the magnitude of 1 to 2 years are necessary to explicate
the long-term efficacy and safety profile of antidepres-
sant administration.
Disappointingly,there are few trials that address main-
tenance phase outcomes in bipolar disorder.For exam-
ple,there are no placebo-controlled maintenance studies
of selective serontonin uptake inhibitors (SSRIs),bupro-
pion, or serotonin-norepinephrine uptake inhibitors
(SNRIs) in bipolar depression. The only published
placebo-controlled,parallel-group maintenance study in
a cohort experiencing an index episode of depression
involves the anticonvulsant lamotrigine.
44 In this study,
patients with BP-I were initially stabilized on lamotrig-
ine for 4 continuous weeks and then randomized to lam-
otrigine (50,200,or 400 mg/day),lithium (serum levels
0.8-1.1 mEq/L), or placebo for up to 18 months.
Lamotrigine,but not lithium,was superior to placebo in
delaying the time to intervention for depressive symp-
toms. A similar finding was observed in a related 18-
month maintenance trial comparing lamotrigine,lithium,
and placebo in recently manic or hypomanic subjects
with BP-I.
45 In this study,lamotrigine was also superior
to placebo in delaying the time to intervention for a
depressive episode.Together,these two maintenance tri-
als support the long-term use of lamotrigine in prevent-
ing new relapses into depression.
In addition to lamotrigine and lithium,other agents such
as olanzapine
46 and aripiprazole
47 have been shown to
prolong the time to relapse during maintenance phase
treatment.Although a maintenance trial of divalproex
did not indicate greater efficacy in preventing the recur-
rence of mania or depression more so than lithium or
placebo,
48 a trend was observed with divalproex in pro-
longing the time to depressive relapse.
49 In summarizing
the collective maintenance trial findings,divalproex,olan-
zapine,and aripiprazole have not been shown to prolong
the time to relapse into a depressive episode.In each of
these studies, patients were required to experience a
recent manic,hypomanic,or mixed episode as opposed
to an episode of major depression. This distinction is
notable,as the index mood episode is highly predictive
of the polarity to which subjects ultimately relapse.
50 In
future investigations, it is imperative that studies be
enriched with subjects who have experienced recent
episodes of depression to help clarify the most appropri-
ate long-term treatments to prevent depressive relapse
and recurrence.Although unpublished at the time of this
writing,quetiapine in combination with lithium or dival-
proex has been studied in two long-term, phase III,
placebo-controlled studies. Treatment with quetiapine
demonstrated a 70% reduction in the risk of recurrence
of a mood event (P<0.001) relative to placebo. This
effect was also seen separately for the prevention of
depression and mania,irrespective of the polarity of the
index episode.
51
Continuation-phase data have also been collected on
patients with BP-I depression who participated in the
previously reported trial of olanzapine and OFC.
52 At
conclusion of the 8-week efficacy trial, subjects were
given the option of receiving open-label OFC or olanza-
pine for up to 24 additional weeks. Although several
design features limit the ability to draw firm conclusions
regarding maintenance efficacy with these agents, it
appears that olanzapine and OFC prolonged the overall
time in remission and allowed a majority of patients to
achieve remission who at the 8-week end point would
otherwise have been designated “nonremitters.”Long-
term treatment with OFC was not associated with an
increased risk for treatment emergent mania.
Future pharmacological considerations for
bipolar depression
With the advent of several new antipsychotic agents,it is
foreseeable that these compounds will also be tested in
patients with bipolar depression. Clinical trials of the
dopamine antagonist asenapine have already been con-
ducted in bipolar I mania,where the agent was shown to
be superior in reducing manic symptoms in comparison
with placebo.
53 Positive results from trials of bifeprunox in
the treatment of schizophrenia have been released,
54 but
to our knowledge no publicly available data is available
regarding this compound’s efficacy in bipolar disorder.
Bifeprunox is a D2 partial agonist that possesses high affin-
ity for 5-HT1A receptors, yet demonstrates rather low
affinity for 5-HT2A,5-HT2C,noradrenergic,muscarinic,and
histaminergic receptors.If found effective in the short- or
long-term relief of bipolar depression, bifeprunox may
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as compared with currently marketed atypical antipsy-
chotics.Pooled data from four 6-week clinical trials,and
one 6-month trial in schizophrenia involving over 1000
subjects found treatment with bifeprunox to be associated
with decreases in body weight and improved total choles-
terol and triglyceride levels.
55
Armodafinil,the R-enantiomer of the wakefulness-pro-
moting agent modafinil, is currently being studied in
Phase II and III trials as adjunctive therapy for the treat-
ment of major depressive episodes associated with BP-I.
Frye and colleagues
56 have demonstrated that the parent
compound modafinil at doses up to 200 mg/day,is ben-
eficial for the adjunctive treatment of major depressive
episodes in BP-I or II.Subjects enrolled in this trial were
inadequately responsive to therapeutic doses or levels of
a mood stabilizer, and some had also failed adjunctive
antidepressants. Using the Inventory of Depressive
Symptoms as the primary outcome measure,nearly twice
as many patients showed a response to adjunctive
modafinil (44%) as with placebo (23%). Although
modafinil is indicated to improve wakefulness,no signif-
icant reductions on standardized measures of sleepiness
or fatigue were observed,despite the observed antide-
pressant efficacy.
Other novel treatments that potentially address putative
etiologic causes for bipolar disorder are under active inves-
tigation.Awaiting analysis and publication are data from
a Phase II multicenter,double-blinded placebo-controlled
study of an oral formulation of uridine in 80 patients with
acute bipolar depression.Uridine is a biological compound
vital to the production of DNA,RNA,and multiple other
factors needed for cell metabolism.Uridine is synthesized
intracellularly within mitochondria.Given the evidence
indicating widespread dysregulation of mitochondrial
energy metabolism in bipolar disorder and Phase I trial
evidence of antidepressant effects for a prodrug of uridine,
this unpublished study attempts to explore the utility of
this natural nucleoside in bipolar depression.
57
Conclusions
Limitations to the available literature on bipolar depres-
sion include a dearth of combination pharmacotherapy tri-
als and inadequate evidence to demonstrate that atypical
antipsychotics or mood stabilizers,with the exception of
lamotrigine or quietapine, robustly prevent depressive
recurrence.Despite the fact that combination therapy is
common practice in bipolar disorder (ie, mean ≥4 psy-
chotropic medications),
58 there is only one placebo-con-
trolled trial to compare combination mood stabilizer treat-
ment (lamotrigine plus lithium) with lithium
monotherapy,
24 and there exist no published placebo-con-
trolled trials that compare combinations of mood stabiliz-
ers and atypical antipsychotics in acute bipolar depression.
Also unanswered is whether particular subgroups of
patients do,in fact,respond positively to the addition of
an antidepressant.Although the STEP-BD acute anti-
depressant trial found no benefit with adjunctive parox-
etine or bupropion,the use of antidepressants in clinical
practice is widespread.
59 Furthermore,investigators have
shown that in patients who remit from a depressive
episode upon receiving antidepressants,discontinuation
of the antidepressant may be associated with higher rates
of depressive relapse.
60Additional studies are therefore
necessary to identify specific populations for which anti-
depressants may be beneficial. Clarification is also
needed regarding the likelihood of inducing mania with
antidepressants,as there has never been a randomized,
placebo-controlled trial to substantiate the assumption
that antidepressants induce new mood episodes of oppo-
site polarity or result in cycle acceleration.
Psychosocial treatments also warrant further investiga-
tion in treating bipolar depression.Though beyond the
scope of this article focused on pharmacological treat-
ments,intensive psychosocial interventions including cog-
nitive behavioral therapy, family focused therapy, and
interpersonal social rhythm therapy were recently found
to accelerate the time to recovery by 110 days as com-
pared with a collaborative care control group.
61The psy-
chosocial treatment arm also led to a modest,but signif-
icantly greater proportion of subjects who eventually met
recovery criteria.
Evidence-based approaches to the treatment of bipolar
depression include the first-line use of lithium,lamotrig-
ine, quetiapine, or OFC. Lithium, when at all possible,
should be dosed with the goal of attaining a blood level
≥0.8 mEq/L as it appears that higher levels are associated
with greater antidepressant efficacy.
18Among anticon-
vulsants,only lamotrigine has been thoroughly studied
for its efficacy in bipolar depression,with prophylactic
benefit potentially outweighing acute antidepressant
effects.The most adequately powered studies of bipolar
depression to date involve the atypical antipsychotic class
of medications.Both OFC and quetiapine have shown
clear superiority over placebo and are reasonable first-
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choice agents.Of atypical antipsychotics,the data most
strongly support quetiapine in the treatment of bipolar
depression,with widespread effects across the core symp-
toms of depression,including an ability to reduce suici-
dal thinking.
33
When patients are nonresponsive or only partially
responsive to a trial of a single mood stabilizer,consid-
erations include switching to an alternate mood stabi-
lizer/atypical antipsychotic, combining mood stabiliz-
ers/atypical antipsychotics,or augmenting with an agent
that may possess clinical, but often less empirical evi-
dence, to support its use. Among mood stabilizers,
lithium,lamotrigine,and divalproex should be given ini-
tial consideration,while among atypical antipsychotics,
only olanzapine and quetiapine are substantiated by trial-
based assessments. Of moderately sized, multicenter
studies, only lamotrigine
24 and modafinil
56 have been
shown to reduce depression more effectively than
placebo when administered adjunctively to a mood sta-
bilizer.For all agents,it should be kept in mind that an
adequate trial consists of at least 6 weeks of treatment.
Over the last decade, we clinicians have witnessed
tremendous advances in our ability to manage the
depressed phase of bipolar disorder.Nevertheless,even
with access to the most novel pharmacological com-
pounds and adherence to research-driven treatment
algorithms,bipolar disorder remains a burdensome and
chronic illness.In as much,less than one third of patients
who achieve recovery are likely to remain well over 2
years of follow-up.
13These sobering outcomes invite the
need for clinical trials seeking to prevent depressive
relapse and to explore whether combination treatments
provide added efficacy, increased effectiveness, and
enhanced recovery.Such trials might employ sequential,
adaptive design schemes that incorporate advances in
our understanding of genomics and the neurobiological
underpinnings of bipolar disorder.It is the expectation
that the next generation of clinical trials will provide
more personalized and predictive treatment options for
those who suffer from this protean disorder. ❏
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Depresión bipolar: reflexiones basadas en
ensayos para orientar el tratamiento del
paciente
Para la mayoría de los pacientes con trastorno
bipolar los episodios depresivos mayores represen-
tan la faceta más desgastadora y difícil en el trata-
miento de la enfermedad. Los pacientes pasan sig-
nificativamente más tiempo depresivos que
maníacos o hipomaníacos y los intentos suicidas
ocurren con mayor frecuencia durante esta etapa
de la enfermedad; aun es limitada la disponibilidad
de tratamientos. Podría decirse que el descubri-
miento de terapias más efectivas para el manejo de
los episodios depresivos es la mayor necesidad insa-
tisfecha en el trastorno bipolar. Este artículo pro-
porciona un resumen de terapias farmacológicas
basadas en la evidencia tanto para el manejo
agudo como longitudinal de la  depresión bipolar.
Se revisan los resultados de ensayos clínicos de una
gran variedad de compuestos, incluyendo estabili-
zadores del ánimo tradicionales (como litio y dival-
proato), antipsicóticos atípicos, antidepresivos uni-
modales y modafinilo. Cuando corresponde, se
examinan las diferencias en la eficacia de estos
compuestos mediante la discusión de las determi-
naciones del número necesario a tratar y de la
magnitud del efecto. Para el manejo de la fase
depresiva del trastorno bipolar se presenta una
aproximación clínica pragmática. 
Dépression bipolaire : réflexion à partir
d’études pour orienter la prise en charge 
du patient
Les épisodes dépressifs majeurs représentent le ver-
sant le plus débilitant et le plus difficile à traiter de
la maladie pour la majorité des patients ayant des
troubles bipolaires. Les patients sont significative-
ment plus longtemps déprimés que maniaques et
hypomaniaques, et c’est pendant cette phase
dépressive de la maladie qu’ils font des tentatives
de suicide, les traitements restant encore limités.
La découverte de traitements plus efficaces pour la
prise en charge des épisodes dépressifs reste sans
doute le besoin le plus insatisfait dans les troubles
bipolaires. Cet article présente un résumé basé sur
les preuves concernant les thérapeutiques phar-
macologiques pour le traitement aigu et longitu-
dinal de la dépression bipolaire. Les résultats des
études cliniques sont revus pour un ensemble de
produits, y compris les thymorégulateurs classiques
(lithium et divalproex), les antipsychotiques aty-
piques, les antidépresseurs unimodaux et le moda-
finil. Le cas échéant, les différences d’efficacité
entre les produits sont discutées par rapport au
nombre de patients à traiter et à la taille d’effet
observée. Une approche clinique pragmatique
pour la prise en charge de la phase dépressive du
trouble bipolaire est présentée.Pharmacological aspects
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